Combining CRISPRi and metabolomics for functional annotation of compound libraries.


Journal

Nature chemical biology
ISSN: 1552-4469
Titre abrégé: Nat Chem Biol
Pays: United States
ID NLM: 101231976

Informations de publication

Date de publication:
05 2022
Historique:
received: 17 02 2021
accepted: 05 01 2022
pubmed: 24 2 2022
medline: 3 5 2022
entrez: 23 2 2022
Statut: ppublish

Résumé

Molecular profiling of small molecules offers invaluable insights into the function of compounds and allows for hypothesis generation about small-molecule direct targets and secondary effects. However, current profiling methods are limited in either the number of measurable parameters or throughput. Here we developed a multiplexed, unbiased framework that, by linking genetic to drug-induced changes in nearly a thousand metabolites, allows for high-throughput functional annotation of compound libraries in Escherichia coli. First, we generated a reference map of metabolic changes from CRISPR interference (CRISPRi) with 352 genes in all major essential biological processes. Next, on the basis of the comparison of genetic changes with 1,342 drug-induced metabolic changes, we made de novo predictions of compound functionality and revealed antibacterials with unconventional modes of action (MoAs). We show that our framework, combining dynamic gene silencing with metabolomics, can be adapted as a general strategy for comprehensive high-throughput analysis of compound functionality from bacteria to human cell lines.

Identifiants

pubmed: 35194207
doi: 10.1038/s41589-022-00970-3
pii: 10.1038/s41589-022-00970-3
pmc: PMC7612681
mid: EMS140722
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

482-491

Subventions

Organisme : European Research Council
ID : 866004
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI139465
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI133191
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018).
pubmed: 29276051 doi: 10.1016/S1473-3099(17)30753-3
Cox, G. et al. A common platform for antibiotic dereplication and adjuvant discovery. Cell Chem. Biol. 24, 98–109 (2017).
pubmed: 28017602 doi: 10.1016/j.chembiol.2016.11.011
Eckhardt, M., Hultquist, J. F., Kaake, R. M., Hüttenhain, R. & Krogan, N. J. A systems approach to infectious disease. Nat. Rev. Genet. 21, 339–354 (2020).
pubmed: 32060427 pmcid: 7839161 doi: 10.1038/s41576-020-0212-5
Imai, Y. et al. A new antibiotic selectively kills Gram-negative pathogens. Nature 576, 459–464 (2019).
pubmed: 31747680 pmcid: 7188312 doi: 10.1038/s41586-019-1791-1
Johnson, E. O. et al. Large-scale chemical–genetics yields new M. tuberculosis inhibitor classes. Nature 571, 72–78 (2019).
pubmed: 31217586 doi: 10.1038/s41586-019-1315-z
Mechanism matters. Nat. Med. 16, 347 (2010).
Campos, A. I. & Zampieri, M. Metabolomics-driven exploration of the chemical drug space to predict combination antimicrobial therapies. Mol. Cell 74, 1291–1303. (2019).
pubmed: 31047795 pmcid: 6591011 doi: 10.1016/j.molcel.2019.04.001
Nonejuie, P., Burkart, M., Pogliano, K. & Pogliano, J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc. Natl Acad. Sci. USA 110, 16169–16174 (2013).
pubmed: 24046367 pmcid: 3791758 doi: 10.1073/pnas.1311066110
Stokes, J. M. et al. A multiplexable assay for screening antibiotic lethality against drug-tolerant bacteria. Nat. Methods 16, 303–306 (2019).
pubmed: 30858599 doi: 10.1038/s41592-019-0333-y
French, S., Coutts, B. E. & Brown, E. D. Open-source high-throughput phenomics of bacterial promoter-reporter strains. Cell Syst. 7, 339–346 (2018).
pubmed: 30172841 doi: 10.1016/j.cels.2018.07.004
Gardner, T. S., Bernardo, D., di, Lorenz, D. & Collins, J. J. Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301, 102–105 (2003).
pubmed: 12843395 doi: 10.1126/science.1081900
Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl. Med. 10, eaal3973 (2018).
pubmed: 29467300 pmcid: 6544516 doi: 10.1126/scitranslmed.aal3973
Zampieri, M. From the metabolic profiling of drug response to drug mode of action. Curr. Opin. Syst. Biol. 10, 26–33 (2018).
doi: 10.1016/j.coisb.2018.05.005
Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14621–14626 (2010).
pubmed: 20679242 pmcid: 2930479 doi: 10.1073/pnas.1000138107
O’Rourke, A. et al. Mechanism-of-action classification of antibiotics by global transcriptome profiling. Antimicrob. Agents Chemother. 64, e01207-19 (2020).
Brötz-Oesterhelt, H., Bandow, J. E. & Labischinski, H. Bacterial proteomics and its role in antibacterial drug discovery. Mass Spectrom. Rev. 24, 549–565 (2005).
pubmed: 15389844 doi: 10.1002/mas.20030
Vincent, I. M., Ehmann, D. E., Mills, S. D., Perros, M. & Barrett, M. P. Untargeted metabolomics to ascertain antibiotic modes of action. Antimicrob. Agents Chemother. 60, 2281–2291 (2016).
pubmed: 26833150 pmcid: 4808186 doi: 10.1128/AAC.02109-15
Fuhrer, T., Heer, D., Begemann, B. & Zamboni, N. High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. Anal. Chem. 83, 7074–7080 (2011).
pubmed: 21830798 doi: 10.1021/ac201267k
Mülleder, M. et al. Functional metabolomics describes the yeast biosynthetic regulome. Cell 167, 553–565 (2016).
pubmed: 27693354 pmcid: 5055083 doi: 10.1016/j.cell.2016.09.007
Sarvin, B. et al. Fast and sensitive flow-injection mass spectrometry metabolomics by analyzing sample-specific ion distributions. Nat. Commun. 11, 3186 (2020).
pubmed: 32581242 pmcid: 7314751 doi: 10.1038/s41467-020-17026-6
Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).
pubmed: 23452860 pmcid: 3664290 doi: 10.1016/j.cell.2013.02.022
Peters, J. M. et al. A comprehensive, CRISPR-based functional analysis of essential genes in bacteria. Cell 165, 1493–1506 (2016).
pubmed: 27238023 pmcid: 4894308 doi: 10.1016/j.cell.2016.05.003
Silvis, M. R. et al. Morphological and transcriptional responses to CRISPRi knockdown of essential genes in Escherichia coli. mBio 12, e0256121 (2021).
Belenky, P. et al. Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage. Cell Rep. 13, 968–980 (2015).
pubmed: 26565910 pmcid: 4648786 doi: 10.1016/j.celrep.2015.09.059
Zampieri, M., Zimmermann, M., Claassen, M. & Sauer, U. Nontargeted metabolomics reveals the multilevel response to antibiotic perturbations. Cell Rep. 19, 1214–1228 (2017).
pubmed: 28494870 doi: 10.1016/j.celrep.2017.04.002
Donati, S. et al. Multi-omics analysis of CRISPRi-knockdowns identifies mechanisms that buffer decreases of enzymes in E. coli metabolism. Cell Syst. 12, 56–67 (2021).
pubmed: 33238135 doi: 10.1016/j.cels.2020.10.011
Fuhrer, T., Zampieri, M., Sévin, D. C., Sauer, U. & Zamboni, N. Genomewide landscape of gene–metabolome associations in Escherichia coli. Mol. Syst. Biol. 13, 907 (2017).
pubmed: 28093455 pmcid: 5293155 doi: 10.15252/msb.20167150
Tatusov, R. L., Galperin, M. Y., Natale, D. A. & Koonin, E. V. The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res. 28, 33–36 (2000).
pubmed: 10592175 pmcid: 102395 doi: 10.1093/nar/28.1.33
You, C. et al. Coordination of bacterial proteome with metabolism by cyclic AMP signalling. Nature 500, 301–306 (2013).
pubmed: 23925119 pmcid: 4038431 doi: 10.1038/nature12446
Costanzo, M. et al. The genetic landscape of a cell. Science 327, 425–431 (2010).
pubmed: 20093466 pmcid: 5600254 doi: 10.1126/science.1180823
de Wet, T. J., Winkler, K. R., Mhlanga, M., Mizrahi, V. & Warner, D. F. Arrayed CRISPRi and quantitative imaging describe the morphotypic landscape of essential mycobacterial genes. eLife 9, e60083 (2020).
pubmed: 33155979 pmcid: 7647400 doi: 10.7554/eLife.60083
Gupta, R., China, A., Manjunatha, U. H., Ponnanna, N. M. & Nagaraja, V. A complex of DNA gyrase and RNA polymerase fosters transcription in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun. 343, 1141–1145 (2006).
pubmed: 16579974 doi: 10.1016/j.bbrc.2006.02.195
Nayar, A. S. et al. Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay. J. Bacteriol. 197, 1726–1734 (2015).
pubmed: 25733621 pmcid: 4402386 doi: 10.1128/JB.02552-14
Spitzer, M. et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7, 499 (2011).
pubmed: 21694716 pmcid: 3159983 doi: 10.1038/msb.2011.31
Amaral, L. & Lorian, V. Effects of chlorpromazine on the cell envelope proteins of Escherichia coli. Antimicrob. Agents Chemother. 35, 1923–1924 (1991).
pubmed: 1952868 pmcid: 245294 doi: 10.1128/AAC.35.9.1923
Feng, Y. et al. Global analysis of protein structural changes in complex proteomes. Nat. Biotechnol. 32, 1036–1044 (2014).
pubmed: 25218519 doi: 10.1038/nbt.2999
Guo, Y. et al. Tail-anchored inner membrane protein elab increases resistance to stress while reducing persistence in Escherichia coli. J. Bacteriol. 199, e00057-17 (2017).
Hu, P. et al. Global functional atlas of Escherichia coli encompassing previously uncharacterized proteins. PLoS Biol. 7, e1000096 (2009).
pmcid: 2672614 doi: 10.1371/journal.pbio.1000096
Lorenz, C., Dougherty, T. J. & Lory, S. Transcriptional responses of Escherichia coli to a small-molecule inhibitor of LolCDE, an essential component of the lipoprotein transport pathway. J. Bacteriol. 198, 3162–3175 (2016).
pubmed: 27645386 pmcid: 5105897 doi: 10.1128/JB.00502-16
Říha, M. et al. Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines. J. Inorg. Biochem. 123, 80–87 (2013).
pubmed: 23563391 doi: 10.1016/j.jinorgbio.2013.02.011
Imlay, J. A. The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium. Nat. Rev. Microbiol. 11, 443–454 (2013).
pubmed: 23712352 pmcid: 4018742 doi: 10.1038/nrmicro3032
Macomber, L. & Imlay, J. A. The iron–sulfur clusters of dehydratases are primary intracellular targets of copper toxicity. Proc. Natl Acad. Sci. USA 106, 8344–8349 (2009).
pubmed: 19416816 pmcid: 2688863 doi: 10.1073/pnas.0812808106
Torres-Cabassa, A. S. & Gottesman, S. Capsule synthesis in Escherichia coli K-12 is regulated by proteolysis. J. Bacteriol. 169, 981–989 (1987).
pubmed: 3029041 pmcid: 211890 doi: 10.1128/jb.169.3.981-989.1987
Hao, Z. et al. The multiple antibiotic resistance regulator MarR is a copper sensor in Escherichia coli. Nat. Chem. Biol. 10, 21–28 (2014).
pubmed: 24185215 doi: 10.1038/nchembio.1380
Kirn, T. J., Onyeaso, E., Syed, M. & Weinstein, M. P. Systematic evaluation of commercial susceptibility testing methods for determining the in vitro activity of daptomycin versus Staphylococcus aureus and Enterococci. J. Clin. Microbiol. 52, 1877–1882 (2014).
pubmed: 24648560 pmcid: 4042769 doi: 10.1128/JCM.03439-13
Peters, J. M. et al. Enabling genetic analysis of diverse bacteria with Mobile-CRISPRi. Nat. Microbiol. 4, 244–250 (2019).
pubmed: 30617347 pmcid: 6424567 doi: 10.1038/s41564-018-0327-z
Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702 (2020).
pubmed: 32084340 pmcid: 8349178 doi: 10.1016/j.cell.2020.01.021
Dubuis, S., Ortmayr, K. & Zampieri, M. A framework for large-scale metabolome drug profiling links coenzyme A metabolism to the toxicity of anti-cancer drug dichloroacetate. Commun. Biol. 1, 101 (2018).
pubmed: 30271981 pmcid: 6123704 doi: 10.1038/s42003-018-0111-x
Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B 64, 479–498 (2002).
doi: 10.1111/1467-9868.00346
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
pubmed: 29555994 pmcid: 6108420 doi: 10.1038/nature25979
Orth, J. D. et al. A comprehensive genome-scale reconstruction of Escherichia coli metabolism–2011. Mol. Syst. Biol. 7, 535 (2011).
pubmed: 21988831 pmcid: 3261703 doi: 10.1038/msb.2011.65
Okuda, S. & Yoshizawa, A. C. ODB: a database for operon organizations, 2011 update. Nucleic Acids Res. 39, D552–D555 (2011).
pubmed: 21051344 doi: 10.1093/nar/gkq1090
Konig, R. et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4, 847–849 (2007).
pubmed: 17828270 doi: 10.1038/nmeth1089
Zampieri, M. et al. Metabolic constraints on the evolution of antibiotic resistance. Mol. Syst. Biol. 13, 917 (2017).
pubmed: 28265005 pmcid: 5371735 doi: 10.15252/msb.20167028
Manfredi, P. et al. Defining proteomic signatures to predict multidrug persistence in Pseudomonas aeruginosa. Methods Mol. Biol. 2357, 161–175 (2021).
pubmed: 34590258 doi: 10.1007/978-1-0716-1621-5_11
Zaslaver, A. et al. A comprehensive library of fluorescent transcriptional reporters for Escherichia coli. Nat. Methods 3, 623–628 (2006).
pubmed: 16862137 doi: 10.1038/nmeth895
Fang, X. et al. Global transcriptional regulatory network for Escherichia coli robustly connects gene expression to transcription factor activities. Proc. Natl Acad. Sci. USA 114, 10286–10291 (2017).
pubmed: 28874552 pmcid: 5617254 doi: 10.1073/pnas.1702581114
Wishart, D. S. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 46, D608–D617 (2018).
pubmed: 29140435 doi: 10.1093/nar/gkx1089
Brunk, E. et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 36, 272–281 (2018).
pubmed: 29457794 pmcid: 5840010 doi: 10.1038/nbt.4072
Faith, J. J. et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 5, e8 (2007).
pubmed: 17214507 pmcid: 1764438 doi: 10.1371/journal.pbio.0050008

Auteurs

Miquel Anglada-Girotto (M)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Gabriel Handschin (G)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Karin Ortmayr (K)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Adrian I Campos (AI)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Ludovic Gillet (L)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Pablo Manfredi (P)

Biozentrum, University of Basel, Basel, Switzerland.

Claire V Mulholland (CV)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA.

Michael Berney (M)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA.

Urs Jenal (U)

Biozentrum, University of Basel, Basel, Switzerland.

Paola Picotti (P)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.

Mattia Zampieri (M)

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland. zampieri@imsb.biol.ethz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH